Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1385-1392

  Lee, Jih Hsiang ^a,b,c   Lin, Yu Lin ^a,d   Hsu, Wei Hsun ^a,b   Chen, Hsuan Yu ^a,e,f   Chang, Yeun Chung ^b   Yu, Chong Jen ^b   Shih, Jin Yuan ^b   Lin, Chia Chi ^a   Chen, Kuan Yu ^b   Ho, Chao Chi ^b   Laio, Wei Yu ^b   Yang, Pan Chyr ^b   Yang, James Chih Hsin ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Graduate Institute of Oncology and Cancer Research Center   (Taiwan)

^d Graduate Institute of Clinical Medicine   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

BIM deletion polymorphism; Non small cell lung cancer; Prognosis

Indexed keywords

BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; DNA; MEMBRANE PROTEIN; ONCOPROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; FEMALE; GENE DELETION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TISSUES; TREATMENT OUTCOME; WILD TYPE; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE; TAIWAN; TRENDS;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; SEQUENCE DELETION; SURVIVAL RATE; TAIWAN;

EID: 84906314041     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000238     Document Type: Article

References (23)

1. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet 2011;378:1727-1740.
2. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
3. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
5. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
6. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of nonsmall- cell lung cancer: recent developments. Lancet 2013;382:709-719.
7. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-528.
8. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
9. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009;8:3173-3180.
10. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
11. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 2010;5:e13026.
12. Faber AC, Corcoran RB, Ebi H, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011;1:352-365.
13. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall- cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
14. Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
15. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-440.
16. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian neversmokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010;28:4616-4620.
17. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-smallcell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154-162.
18. Kao HF, Lin CC, Yang JC. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol 2013;9:991-1003.
19. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874.
20. Inoue A, Kobayashi K, Maemondo M, et al.; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve nonsmall cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54-59.
21. Costa C, Molina-Vila MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001-2010.
22. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845-1853.
23. Li R, Moudgil T, Ross HJ, Hu HM. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005;12:292-303.